Loading...
Market
Where will Winrevair rank among Merck's top products by sales by the end of 2025?
2
Resolution / Starting Odds
Top 3 • 25%
Top 5 • 25%
Top 10 • 25%
Below Top 10 • 25%
Merck's annual financial report for 2025
Story
Merck's Winrevair Shows Positive Results in Phase 3 Trial, Reducing Risk of Death
Nov 25, 2024, 12:00 PM
Merck announced on Monday that its drug, Winrevair (sotatercept-csrk), has shown significant results in reducing the risk of death in patients with a rare lung condition that causes high blood pressure. The announcement follows the Pivotal Phase 3 ZENITH Trial, which met its primary endpoint at an interim analysis. This development comes months after the drug secured approval in the United States.
View original story
Similar markets
Yes • 50%
No • 50%
Increase by more than 5% • 25%
Increase by 0-5% • 25%
No significant change • 25%
Decrease • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
1st • 25%
2nd • 25%
3rd • 25%
4th or lower • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%
Revuforj holds the largest market share • 25%
Revuforj holds the second largest market share • 25%
Revuforj holds the third largest market share • 25%
Revuforj holds less than third place in market share • 25%
